At some point you may have had a reaction to penicillin and were told you were allergic. And there’s a good chance it has stayed in your chart throughout your childhood and into adulthood. But 9 of 10 Americans who think they have a penicillin allergy have either outgrown it or never had it in the first place. That said, it’s important to get tested by an allergist to know if you have a true penicillin allergy so you know whether to avoid the drug.
Did you know pollen might be responsible for your food allergy? If your mouth or throat itch when you eat certain fruit or vegetables, you could have oral allergy syndrome (OAS). And you would have a pollen allergy to thank for that.
The Asthma and Allergy Foundation of America (AAFA), the premiere nonprofit representing patients with asthma and allergies, applauds the recent request for information and statement from the Food and Drug Administration (FDA) demonstrating its commitment to explore the classification of sesame as a major allergen.
On behalf of the more than 60 million Americans with asthma and allergies – many of whom depend on life-saving medications – the Asthma and Allergy Foundation of America (AAFA) applauds Senators Chuck Grassley and Ron Wyden for holding hearings on drug pricing in America. This series of hearings demonstrates the senators’ commitment to exploring the problem of overpriced medications in America.
Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® available through Walgreens locations nationwide. The Asthma and Allergy Foundation of America (AAFA) applauds this effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.
AAFA does not support the changes proposed by USP because we believe they pose a real threat to quality of care. We strongly urge the USP to keep existing guidelines for allergen immunotherapy in place so that millions of patients across the United States can continue to receive the treatment they need.
[Press Release] PR Contact: Adam Bailine, Vice President, Marketing & Communications (202) 466-7643, ext. 254 email@example.com AAFA Co-Sponsored Report Provides Recommendations for Food Allergy Research, Treatment, and Policy With support from the Asthma and Allergy Foundation of America (AAFA), the National Academies of Sciences, Engineering, and Medicine releases a monumental report that makes recommendations to increase our understanding of and approaches to food allergies November...
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).
When new drugs and medical procedures are developed, they go through rigorous scientific study. Complementary Alternative Medicine treatments usually do not go through the same type of research. As a result, whether it works (called efficacy) is unproven for most treatments. Most herbal remedies for rhinitis fall into that category.
This post discusses claims that caffeine can be used to treat asthma symptoms. It is part of our “ AAFA Explains ” series looking at complementary and alternative medicine (CAM) aimed at asthma and allergies. The Asthma and Allergy Foundation of America (AAFA) wants to guide you as you decide between choices that may be “likely safe” or “potentially unsafe.” What is asthma? Asthma is a chronic disease that causes your airways to become inflamed, making it hard to breathe. There is no cure...
The Asthma and Allergy Foundation of America (AAFA) cautions parents raising children with food allergies that some scenes in the newly-released “Peter Rabbit” film may be disturbing for young viewers with food allergies. In the film, a character with a known food allergy to blackberries is attacked with them. This leads to a severe allergic reaction known as anaphylaxis and the need to use a lifesaving injection of the drug epinephrine.
The I Am Essential coalition, submitted comments, signed by 97 patient groups, to the U.S. Department of Health and Human Services in opposition to the Trump Administration's proposed rule that would expand the scope and applicability of short-term, limited-duration insurance plans (short-term plans). The rule, if finalized, would have a crippling effect on individuals' healthcare.
Access to proper health care coverage is essential and life-saving for people with asthma and allergies. The Asthma and Allergy Foundation of America has joined other patient groups to make up the I Am Essential coalition to advocate against changes that could threaten health care coverage for those we serve. This press release outlines the coalition's concerns about these proposed changes.
Manufacturing and insurance issues have made it hard for many members of our community to fill their prescriptions for epinephrine auto-injectors in recent months. But the drug epinephrine itself is not in short supply. This has become a serious concern for families of children with life-threatening food allergies. When families who manage food allergies are in fear for their children's lives because they can't get the medicine they need, our system is broken.
Asthma and allergies impact one in five children in the United States. The Asthma and Allergy Foundation of America (AAFA) exhibited at the 2019 American Academy of Pediatrics (AAP) conference to learn the latest news in pediatrics and to talk to health care providers about the programs and services we offer.
Biologics are a new class of drugs that fight disease at the source . Instead of attacking symptoms, these drugs target diseases like asthma at a molecular level. These newer types of drugs are more expensive than older medicines. That is prompting public discussion on how to pay for them. The cost of caring for patients with the most severe forms of asthma represents a majority of asthma healthcare spending. In addition, asthma is a leading cause of missed time from work and school. Last...
These are just a few things we were able to do this year for the asthma and allergy community because of you. But there is more for us to do to significantly reduce the burden of these diseases on people with asthma and allergies. And we can with your help.
According to the Food and Drug Administration (FDA), Mylan is discontinuing Aerospan® (80 mcg). Aerospan is a corticosteroid inhaler used for daily asthma maintenance. Mylan notified the FDA on Jan. 26, 2018.
The Asthma and Allergy Foundation of America is sharing this message from the American College of Allergy, Asthma and Immunology (ACAAI)for people with asthma about a shortage of albuterol metered dose inhalers
The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperature
Congressmen Eliot L. Engel (D-NY) and Fred Upton (R-MI), Co-Chairs of the Asthma and Allergy Caucus, joined by Congressmen TJ Cox (D-CA) and Peter King (R-NY), Members of Caucus, led 57 Members of the House on a letter to the Food and Drug Administration (FDA) about shortages of albuterol inhalers, which are critical to effective asthma management.
The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.
Essential oils, like herbal remedies, come from plants. Practitioners of traditional and folk medicine (usually meaning those without a medical degree) have used essential oils for thousands of years, much like herbal remedies. Is there any evidence to back up claims that essential oils can help my asthma?
Because of the COVID-19 (new coronavirus) pandemic, we are facing a challenging and unprecedented time. COVID-19 is a respiratory infection, and the nearly 25 million Americans with asthma are at high risk for complications from the virus. As the leading patient organization for people with asthma and allergies, this has the Asthma and Allergy Foundation of America (AAFA) deeply concerned for your health and well-being.
During the holiday season, our calendars fill up with a lot of social activities. More often than not, these include food. If you or a member of your family has a food allergy, these events can be more stressful than fun. Follow these tips to keep everyone safe from accidental allergic reactions.
By Megan Roberts, Community Engagement Program Manager at the Asthma and Allergy Foundation of America This post is a follow up to Breathing in the Boat: Dragon Boat World Championships With Asthma . Paddling is my passion. I’ve raced boats in half of the world’s oceans, Hungary, Italy, Hawaii, Canada, Puerto Rico and all over the United States. I have not, however, ever had the opportunity before 2017 to race in China, the birthplace of the sport of dragon boating more than 2,500 years ago.
The U.S. House of Representatives has declared their support for National Asthma and Allergy Awareness Month . Reps. Eliot Engel (D-NY), Fred Upton (R-MI), TJ Cox (D-CA) and Peter King (R-NY) submitted the resolution to the House Committee on Energy and Commerce on May 8, 2020. May is peak season for people with asthma and allergies. That’s why the Asthma and Allergy Foundation of America (AAFA) chose it as a time to raise awareness and educate people on how to manage these conditions. Read...
Could drones be used someday to deliver life-saving medications or interventions in the case of a child’s emergency, a drug overdose or in response to a mass casualty scene? According to new research presented at the American Academy of Pediatrics 2019 National Conference & Exhibition, it’s an idea worth exploring.
The Asthma and Allergy Foundation of America (AAFA) has been fighting to save lives for nearly 70 years. With your support, we provide education, conduct patient-centered research and advocate for protections for our community. Our experience and strong community ties allowed us to take prompt action on the COVID-19 crisis . Thanks to your generous support, we are leading the fight against COVID-19 for people with asthma and allergies. But we need your help to continue to provide COVID-19...
Holly Hill, FL, Product Quest Manufacturing (“Product Quest”) is voluntarily recalling Lot# 173089J of CVS Health 12 Hour Sinus Relief Nasal Mist, a clear, colorless liquid, to the consumer level. The product was found to have had microbiological contamination identified as Pseudomonas aeruginosa.
Many of our members in Houston, and the surrounding areas of Texas and into Louisiana, continue to be affected by Hurricane Harvey and the ensuing flooding.
If you are in the affected area and want to help, we have listed the name of an agency who is accepting allergy-friendly food donations, with delivery instructions so the food can make it safely to those who need it.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
Join the Asthma and Allergy Foundation of America and Kids With Food Allergies for a back-to-school Facebook chat. Attorney, author and food allergy advocate Laurel Francoeur, Esq., will answer your questions on how to send your child with asthma and food allergies back to school with the right accommodations to keep them safe.
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
FDA News Release FDA approves Cinqair to treat severe asthma For Immediate Release March 23, 2016 Inquiries Media Andrea Fischer 301-796-0393 Consumers 888-INFO-FDA Release The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current...
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype
and oral corticosteroid-dependent asthma, regardless of phenotype.
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.
The U.S. Food and Drug Administration today approved the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The U.S. Food and Drug Administration today approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.
FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .